JohnASunyeczMD

PubMed

• 1 citations
  Vaginal cuff closure during total laparoscopic hysterectomy: a new technique has been performed 100 times with very few complications.
  John A. Sunyecz> ;American Journal of Obstetrics and Gynecology. 2013 Jul 1
• 7 citations
  Zoledronic acid infusion for prevention and treatment of osteoporosis.
  John A Sunyecz> ;International Journal of Women's Health. 2010 Oct 14
• Ibandronate and Nonvertebral Fracture Efficacy: Results of a Recent Pooled Analysis
  John A Sunyecz> ;The Physician and Sportsmedicine. 2010 Jun 1
• 1 citations
  Once-a-month risedronate in postmenopausal osteoporosis. Commentary.
  John A Sunyecz> ;Postgraduate Medicine. 2009 Jul 1
• Comment on an article reviewing black cohosh and case reports of hepatotoxicity.
  John A Sunyecz> ;Menopause. 2009 Jan 1
• 8 citations
  Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations
  John Sunyecz> ;Clinical Interventions in Aging. 2008 Dec 5
• 129 citations
  The use of calcium and vitamin D in the management of osteoporosis
  John A Sunyecz> ;Therapeutics and Clinical Risk Management. 2008 Aug 8
• 34 citations
  Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
  J. A. Sunyecz, L. Mucha, O. Baser, Charles E. Barr, M. M. Amonkar> ;Osteoporosis International. 2008 Mar 20
• 4 citations
  Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists.
  John A Sunyecz, Richard J. Derman> ;Obstetrical & Gynecological Survey. 2007 Jun 1
• 13 citations
  The role of calcium in osteoporosis drug therapy.
  John Alexander Sunyecz, Steven M. Weisman> ;Journal of Women's Health. 2005 Mar 17
• 2 citations
  Lymphoproliferative Disorder Involving the Cervix in a Patient Being Treated with FK-506
  John A. Sunyecz, Fredric V. Price, Giuliana Trucco, Robert Thomas, Steven H. Swerdlow> ;Gynecologic Oncology. 1996 Aug 1
• Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.
  Binkley, N., Silverman, S. L., Simonelli, C., Santiago, N., Kohles, J. D., Dasic, G., Sunyecz, J. A.> ;Osteoporos Int. 2009 Sep 01
• 7 citations
  The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis
  J. A. Sunyecz, H. C. Wiesenfeld, R. P. Heine> ;Infectious Diseases in Obstetrics and Gynecology. 1998 Jan 1
• Join now to see all

Abstracts/Posters

• Monthly Ibandronate Suppresses Serum CTX-1 Within 3 Days and Maintains a Monthly Fluctuating Pattern of Suppression.
  Binkley, N, Silverman, S, Simonelli, Sunyecz, J, Santiago, Kohles, Dasic, Osteoporosis International
• The Use of Combination Therapy in Osteoporosis: Bisphosphonates Calcium and Vitamin D.
  Sunyecz, JA, PowerPak CE
• Changing Awareness and Management of Calcium and Vitamin D Deficiencies: The Role of the Pharmacist in Bone Health and Osteoporosis.
  Sunyecz, JA, PowerPak CE
• Persistence with monthly ibandronate and weekly bisphosphonates: an early look.
  Silverman, SL, Derman, R, Sunyecz, J, et al, North American Menopause Society Meeting
• Healthcare costs and utilization are reduced for women adherent to bisphosphonate therapy.
  Sunyecz, J, Curtis, JR, Barr, C, et al, North American Menopause Society Meeting
• Continued improvement in bone mineral density observed from 1 to 2 years after treatment with monthly oral ibandronate.
  Sunyecz, J, Lewiecki, EM, Emkey, R, et al, North American Menopause Society Meeting
• Consistent improvement in bisphosphonate persistence with less frequent dosing: Review comparing results of three database studies.
  Gold, D.T., Cramer, J.A., Sunyecz, J.A., Amonkar, M.M., Ettinger, M.P, International Society for Clinical Densitometry
• Review of 3 Claims Database Studies: Consistent Improvement in Bisphosphonate Persistence with Less Frequent Dosing.
  Gold, D, Sunyecz, J. Kamel, H, Leslie, R, 14 th Annual Congress on Women’s Health
• Better adherence to bisphosphonate therapy is associated with reduced nonvertebral fracture risk.
  Sunyecz, J.A., Bachman, G., Abbottt, T., Barr, C, ACOG Annual Clinical Meeting
• Mobile 2 Year: Efficacy and tolerability of once-monthly ibandronate in postmenopausal osteoporosis.
  Dasic, G, Lewiecki, E, Miller, P, Sunyecz, J, Emkey, R, ACOG Annual Clinical Meeting
• Improving Patient Outcomes with Osteoporosis Drug Therapy.
  Sunyecz, JA, PowerPak CE
• Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis.
  Sunyecz, J.A., Gallaher, R., MacCosbe, P.E, The Female Patient
• Women’s stated preference for once-monthly versus once-weekly osteoporosis treatment regimens.
  Utian, W, Sunyecz, J.A, ACOG Annual Clinical Meeting
• Better clinical response for once-monthly versus daily oral ibandronate.
  Sunyecz, J.A, ACOG Annual Clinical Meeting
• Changing Awareness and Management of Calcium and Vitamin D Deficiencies: The Role of the Pharmacist in Bone Health and Osteoporosis.
  Sunyecz, JA, PowerPak CE
• Persistence with monthly ibandronate and weekly bisphosphonates: an early look.
  Silverman, SL, Derman, R, Sunyecz, J, et al, North American Menopause Society Meeting
• Healthcare costs and utilization are reduced for women adherent to bisphosphonate therapy.
  Sunyecz, J, Curtis, JR, Barr, C, et al, North American Menopause Society Meeting
• Continued improvement in bone mineral density observed from 1 to 2 years after treatment with monthly oral ibandronate.
  Sunyecz, J, Lewiecki, EM, Emkey, R, et al, North American Menopause Society Meeting
• Consistent improvement in bisphosphonate persistence with less frequent dosing: Review comparing results of three database studies.
  Gold, D.T., Cramer, J.A., Sunyecz, J.A., Amonkar, M.M., Ettinger, M.P, International Society for Clinical Densitometry
• Review of 3 Claims Database Studies: Consistent Improvement in Bisphosphonate Persistence with Less Frequent Dosing.
  Gold, D, Sunyecz, J. Kamel, H, Leslie, R, 14 th Annual Congress on Women’s Health
• Days of therapy improve with weekly dosing, but remain inadequate.
  Sunyecz, J.A., Gallagher, R., Smith, J.C., MacCosbe, P.E, North American Menopause Society meeting, Washington, D.C
• Menopausal women’s current impressions of hormonal therapy.
  Sunyecz, J.A., Drexler, A.J, North American Menopause Society meeting, Washington, D.C
• Average woman experiences nearly seven symptoms of menopause plus other health concerns.
  Sunyecz, J.A., Drexler, A.J, North American Menopause Society meeting, Washington, D.C
• The effect of a menopause Internet site on the dissemination of education and information and its influence on health care practices.
  Sunyecz, J.A., Sunyecz, L.A, North American Menopause Society meeting, Chicago, IL
• The effect of the “Perimenopause and Menopause Survival Kit” in providing information and recommendations for the menopause transition.
  Sunyecz, J.A., Sunyecz, L.A, North American Menopause Society meeting, Chicago, IL
• Join now to see all

Lectures

• Total Laparoscopic Hysterectomy: Achieving the Best Technique for Vaginal Cuff Closure. 
  AAGL Global Congress of Minimally Invasive Gynecology
• Making Menopause Manageable. 
  29 th Annual CME Conference of Virginia Academy of Physician Assistants. Virginia Beach, VA
• Amgen. Numerous presentations to Health Care Providers related to Osteoporosis management and treatment options. 
• The Use of a Vaginal Moisturizer Containing Vitamin B3 (Vibrel™ for Women) in Perimenopausal and Menopausal Women Complaining of Sexual Dysfunction: Results of a Pil... 
  North American Menopause Society meeting, San Diego, CA
• Similar Bone Mineral Density Gains for Oral Monthly Ibandronate and Weekly Alendronate in Postmenopausal Osteoporosis. 
  American College of Ob/Gyn Annual Clinical Meeting, New Orleans
• Ortho Women’s Health & Urology. Numerous presentations to Health Care Providers related to Interstitial Cystitis diagnosis and treatment options. 
• Roche/GSK. Numerous presentations related to Osteoporosis diagnosis and treatment options. 
• Pregnancy: An Ob/Gyn’s Perspective. 
  GSK Calcium Summit, Pittsburgh, PA
• Practitioner Panel: Osteoporosis. Pharmaceutical Representatives. 
  Roche Pharmaceuticals, Boston, MA
• Abnormal Bleeding…Alternatives to Hysterectomy. 
  local community group
• Hormone Therapy…Bio-Identical Treatment Options. 
  Wheeling, WV Ob/Gyn Society
• Practitioner Panel: Osteoporosis. 
  Pharmaceutical Representatives, Exceeding Expectations Meeting, Roche Pharmaceuticals, Las Vegas
• Explore the differences between the menopause and perimenopause, including symptoms and treatment options by a board certified gynecologist. Learn about the importan... 
  Pathways to Beauty and Well-Being Event
• Relationship of Weight and Oral Contraceptive Use Failure. 
  Ob/Gyn roundtable
• Stress Incontinence: Pathophysiology and Treatment Options. 
  GSK scientific committee
• Review of ACET Trial for Urinary Incontinence. 
  Pharmacia representatives, teleconference
• Calcium in Pregnancy and Beyond. 
  GlaxoSmithKline representatives, Orlando, FL
• Beyond Oral Contraceptives: Improving the Quality of Life for the Female Patient. 
  CME presentation to Wheeling, WVa. Ob/Gyn meeting
• Bio-Identical Hormone Therapy…Is it natural? Is it better? 
  Consumer educational brochure, produced for MenopauseRx, Inc
• Panelist for ‘The Surgeon General's Report on Bone Health: Applications for the Clinician. 
  Medical Crossfire
• Panelist for ‘Managing Menopausal Symptoms in the Wake of WHI’ Medical Crossfire. 
• Clinical Advisory Member for 'Postpartum Counseling Guide - A quick reference guide for clinicians'. 
  ARHP
• Join now to see all